Drugs / iPSC-derived islet cell
last change Mar 2026 re-read 3 minutes ago

iPSC-derived islet cell

Cell therapy

Developed for
diabetes mellitus
Investigated by
Hangzhou Reprogenix Bioscience, Inc · Peking University First Hospital

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT07464119 Mar 2026 → Dec 2028 expected diabetes mellitus Peking University First Hospital Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as iPSC-derived islet cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT07464119 ↗
Modality Cell therapy “iPSC-derived islet cell infusion” NCT07464119 ↗